Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities

AIDS

Volumn 12, Issue 16, 1998, Pages 2115-2123

  Bisset, Leslie R ^a   Cone, Richard W ^a   Huber, Werner ^a   Battegay, Manuel ^b   Vernazza, Pietro L ^c   Weber, Rainer ^a   Grob, Peter J ^a   Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Asymptomatic; Highly active antiretroviral therapy; HIV; T cell subsets

Indexed keywords

CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; LAMIVUDINE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ACUTE DISEASE; ADP-RIBOSYL CYCLASE; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION; BIOLOGICAL MARKERS; FEMALE; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; LAMIVUDINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; T-LYMPHOCYTES; VIRAL LOAD; ZIDOVUDINE;

EID: 0032511914     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00006     Document Type: Article

References (53)

1. Schnittman SM, Fox L: Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. AIDS Res Hum Retroviruses 1997, 13:815-818.
2. Roederer M: Getting to the HAART of T cell dynamics. Nat Med 1998, 4:145-146.
3. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
4. Emery S, Lane HC: Immune reconstitution in HIV infection. Curr Opin Immunol 1997, 9:568-572.
5. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced disease. Science 1997, 277:112-116.
6. Autran JB, Mathez D, Carcelain G, Blanc C, Debre P, Leibowitch J: Dynamics of the CD4 T helper cell subset reconstitution after combined anti-retroviral therapies. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January1997 [abstract 34].
7. Pakker NG, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-214.
8. Pantaleo G, Graziosi C, Butini L, et al.: HIV is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-360.
9. Piatak M, Saag M, Yang L, et al.: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
10. Stellbrink H-J, van Lunzen J, Hufert FT, et al.: Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells. AIDS 1997, 11:1103-1110.
11. Perrin L, Yerly S, Lazzarin A, et al.: Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZT-ddl. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeB532].
12. Markowitz M, Cao Y, Hurley A, et al.: Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB933].
13. Saimot AG, Simon F, Landman R, et al.: A triple nucleoside analogue combination in four patients with primary HIV-1 infections: towards virological remissions? XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1332].
14. Kinloch-De Loes S, Hirschel B, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
15. Markowitz M, Cao Y, Vesanen M, et al.: Recent HIV infection treated with AZT, 3TC and a potent protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB8].
16. Stellbrink H-J, Zöller B, Fenner T, et al.: Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. AIDS 1996, 10:849-857.
17. Fahey JL, Prince H, Weaver M, et al.: Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med 1984, 76:95-100.
18. Giorgi JV, Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989, 52:10-18.
19. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W: Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. AIDS 1989, 2:63-69.
20. Margolirk JB, Munoz A, Vlahov D, et al.: Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. AIDS 1993, 6:153-161.
21. Margolick JB, Muñoz A, Donnenberg AD, et al.: Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995, 1:674-680.
22. Gruters RA, Miedema F: T lymphocyte functional defects in HIV infection. In Immunodeficiency in HIV Infection and AIDS. Edited by Janossy G, Autran B, Miedema F. Basel: Karger, 1992:135-144.
23. Roederer M, Dubs JG, Anderson MT, Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95:2061-2066.
24. van Noesel CJ, Gruters RA, Terpstra FG, Schellekens PT, Van Lier RA, Miedema F: Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest 1990, 86:293-299.
25. De Paoli P, Carbone A, Battistin S, Crovatto M, Arreghini N, Santini G: Selective depletion of the OKT4+ 4B4+ subset in lymph nodes from HIV+ patients. Immunol Lett 1987, 16:71-77.
26. Ullum H, Cozzi Lepri A, Victor J, Skinhøj P, Phillips AN, Pedersen Klarlund B: Increased loss of CD4+CD45RA+ cells in late stages of HIV infection is related to increased risk of death: evidence from a cohort of 347 HIV-infected individuals. AIDS 1997, 11:1479-1485.
27. Biberfeld P, Øst Å, Porwit A, et al.: Histopathology and immunopathology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A 1987, 95:47-65.
28. Røsok BI, Bostad L, Voltersvik P, et al.: Reduced CD4 cell counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV-1 infection. AIDS 1996, 10:F35-F38.
29. Cohen OJ, Pantaleo G, Lam GK, Fauci AS: Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol 1997, 18:305-322.
30. Centers for Disease Control and Prevention: 1997 Revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997, 46:1-29.
31. Rosenberg YJ, Anderson AO, Pabst R: HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol Today 1998, 19:10-17.
32. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
34. Yagi MJ, Joesten ME, Wallace J, Roboz JP, Bekesi JG: Human immunodeficiency virus type 1 (HIV-1) genomic sequences and distinct changes in CD8+ lymphocytes precede detectable levels of HIV-1 antibodies in high-risk homosexuals. J Infect Dis 1991, 164:183-188.
35. Giorgi JV, Ho H-N, Hirji K, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994, 170:775-781.
36. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA: The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992, 90:376-382.
37. Benito JM, Zabay JM, Gil J, et al.: Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:128-135.
38. Kestens L, Vanham G, Vereecken C, et al.: Selective increase of activation antigens HLA-DR and CD38 on CD4+CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994, 95:436-441.
39. Ascher MS, Sheppard HW: AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988, 73:165-167.
40. Grossman Z, Bentwich Z, Herberman RB: From HIV infection to AIDS: are the manifestations of effective resistance misinterpreted? Clin Immunol Immunopathol 1993, 69:123-135.
41. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV: Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:83-92.
42. Bouscarat F, Levacher-Clergeot M, Dazza M-C, et al.: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996, 12:17-24.
43. Ho HN, Hultin LE, Mitsuyasu RT, et al.: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993, 150:3070-3079.
44. Klenerman P, Zinkernagel RM: What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 1997, 159:5-16.
45. Dutton RW, Bradley LM, Swain SL: T cell memory. Annu Rev Immunol 1998, 16:201-223.
46. Helbert MR, Walter J, L'Age J, Beverley PCL: HIV infection of CD45RA+ and CD45RO+ CD4+ T cells. Clin Exp Immunol 1997, 107:300-305.
47. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS: Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective functional defects observed in HIV infected individuals. Proc Natl Acad Sci USA 1990, 87:6058-6062.
48. Spina CA, Prince HE, Richman DD: Preferential replication of HIV-1 in the CD45RO memory cell subset of primary lymphocytes in vitro. J Clin Invest 1997, 99:1774-1785.
49. Chun T-W, Chadwick K, Margolick J, Siliciano RF: Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol 1997, 71:4436-4444.
50. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiretroviral or immune-based therapies. Nat Med 1997, 3:533-540.
51. Mahalingam M, Pozniak A, McManus TJ, Senaldi G, Vergani D, Peakman M: Abnormalities of CD45 isoform expression in HIV infection. Clin Immunol Immunopathol 1996, 81:210-214.
52. Li TS, Tubiana R, Katlama C, Calvez V, Ait Hohand H, Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
53. Gray CM, Schapiro JM, Winters MA, Merigan TC: Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998, 14:561-569.